{"id":"W4286561096","doi":"10.1038/s41416-022-01903-6","title":"Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer","year":2022,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"AstraZeneca","keywords":"Selumetinib; Gemcitabine; Medicine; Chemotherapy; MEK inhibitor; Cisplatin; Internal medicine; Toxicity; Oncology; Urology; Gastroenterology; Surgery; Cancer; MAPK/ERK pathway; Biology; Kinase; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002432585,0.002275628,0.004529085,0.0005731393,0.0005664344,0.00170304,0.001275189,0.002035713,0.009806714],"category_scores_gemma":[0.002898949,0.001635178,0.003006159,0.0007371679,0.001954702,0.001753269,0.0008564816,0.005000419,0.001704807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001634578,"about_ca_system_score_gemma":0.002088892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002870618,"about_ca_topic_score_gemma":0.006644536,"domain_scores_codex":[0.9987432,0.0008053835,0.00006230472,0.0001710274,0.00006104728,0.0001570258],"domain_scores_gemma":[0.9982939,0.0004418108,0.0002942249,0.0001958823,0.0001154072,0.00065873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9840763,0.005532705,0.0004463315,0.0002924876,0.0009402289,0.00002768962,0.00005303996,0.0003953867,0.001961407,0.00007626953,0.0005360562,0.005662119],"study_design_scores_gemma":[0.9421484,0.0556012,0.000996932,0.00001199535,0.0003098411,0.0000192093,0.00002474882,0.0001204461,0.0001490501,0.00007477155,0.0005328428,0.00001054899],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825783,0.003671759,0.0008711771,0.00117938,0.001160232,0.004945489,0.001884552,0.0001235373,0.003585549],"genre_scores_gemma":[0.9770949,0.00349568,0.00187191,0.001900038,0.0006226464,0.005348488,0.002729446,0.0000607137,0.006876123],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009806714,"threshold_uncertainty_score":0.03280675,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01100035852035191,"score_gpt":0.2962305676332977,"score_spread":0.2852302091129458,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}